For citations:

Nasonov E.L., Feist E. The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6). Rheumatology Science and Practice. 2022;60(5):505-518. (In Russ.) https://doi.org/10.47360/1995-4484-2022-505-518